temozolomide has been researched along with Colon Cancer, Familial Nonpolyposis in 3 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mismatch repair-deficient (MMRD) brain tumors are rare among primary brain tumors and can be induced by germline or sporadic mutations." | 1.72 | Sporadic and Lynch syndrome-associated mismatch repair-deficient brain tumors. ( Choi, SH; Kang, J; Kim, H; Kim, SK; Kim, TM; Lee, K; Lim, KY; Park, CK; Park, JW; Park, SH; Shim, Y; Won, JK; Yun, H, 2022) |
| "We developed a mouse model of Lynch syndrome (Lgr5-CreERT2;Msh2(flox/-) mice) and found that environmental factors can modify the number and mutability of the MMR-deficient stem cells." | 1.40 | Temozolomide increases the number of mismatch repair-deficient intestinal crypts and accelerates tumorigenesis in a mouse model of Lynch syndrome. ( Cantelli, E; De Vries, S; Dekker, M; Delzenne-Goette, E; Plug, M; Song, JY; Te Riele, H; Van Der Wal, A; Van Gerwen, B; Wojciechowicz, K, 2014) |
| "Members of hereditary nonpolyposis colon cancer (HNPCC) families harboring heterozygous germline mutations in the DNA mismatch repair genes hMSH2 or hMLH1 present with tumors generally two to three decades earlier than individuals with nonfamilial sporadic colon cancer." | 1.31 | Tolerance of human MSH2+/- lymphoblastoid cells to the methylating agent temozolomide. ( Bartosova, Z; Bonmassar, L; Cattaruzza, MS; Corti, C; D'Atri, S; Heinimann, K; Jiricny, J; Marra, G; Nyström-Lahti, M; Schweizer, P, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, H | 1 |
| Lim, KY | 1 |
| Park, JW | 1 |
| Kang, J | 1 |
| Won, JK | 1 |
| Lee, K | 1 |
| Shim, Y | 1 |
| Park, CK | 1 |
| Kim, SK | 1 |
| Choi, SH | 1 |
| Kim, TM | 1 |
| Yun, H | 1 |
| Park, SH | 1 |
| Wojciechowicz, K | 1 |
| Cantelli, E | 1 |
| Van Gerwen, B | 1 |
| Plug, M | 1 |
| Van Der Wal, A | 1 |
| Delzenne-Goette, E | 1 |
| Song, JY | 1 |
| De Vries, S | 1 |
| Dekker, M | 1 |
| Te Riele, H | 1 |
| Marra, G | 1 |
| D'Atri, S | 1 |
| Corti, C | 1 |
| Bonmassar, L | 1 |
| Cattaruzza, MS | 1 |
| Schweizer, P | 1 |
| Heinimann, K | 1 |
| Bartosova, Z | 1 |
| Nyström-Lahti, M | 1 |
| Jiricny, J | 1 |
3 other studies available for temozolomide and Colon Cancer, Familial Nonpolyposis
| Article | Year |
|---|---|
Sporadic and Lynch syndrome-associated mismatch repair-deficient brain tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain; Brain Neoplasm | 2022 |
Temozolomide increases the number of mismatch repair-deficient intestinal crypts and accelerates tumorigenesis in a mouse model of Lynch syndrome.
Topics: Adenocarcinoma; Adenoma; Animals; Cell Proliferation; Cell Transformation, Neoplastic; Colorectal Ne | 2014 |
Tolerance of human MSH2+/- lymphoblastoid cells to the methylating agent temozolomide.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Alkylating; Carrier Proteins; Cell Line | 2001 |